Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.72 |
| ▸ | AGTR2 | P50052 | 14/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7828413 | 0.97 | AGTR1 (0.69) | AGTR1AGTR2 | |
| SCHEMBL7827186 | 0.96 | AGTR1 (0.68) | AGTR1AGTR2 | |
| SCHEMBL7833628 | 0.96 | AGTR1 (0.68) | AGTR1AGTR2 | |
| SCHEMBL7399866 | 0.96 | AGTR1 (0.73) | AGTR1AGTR2 | |
| SCHEMBL7819006 | 0.95 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL7827242 | 0.94 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL7398914 | 0.94 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL7833154 | 0.94 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL7398978 | 0.93 | AGTR1 (0.71) | AGTR1AGTR2 | |
| SCHEMBL7828364 | 0.92 | AGTR1 (0.72) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | G.D. SEARLE & CO. (US) | 2001-09-06 | — | — | US | claimed |
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | G.D. SEARLE & CO. (US) | 2001-09-06 | — | — | US | disclosed |
| EP-0412594-B1 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO INC (US) | 1996-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | NR3C2, AGTR1, PAH | AGTR1 2/4885AGTR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.